Clinical Trial Update: Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) [Phase 4]

View source ↗

Summary

Phase 4 trial update on elbasvir plus grazoprevir in treatment-naïve and treatment-experienced French participants with HCV genotype 4; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C Virus (HCV) Infection | Phase 4 | Status: COMPLETED | Results posted: 2019-11-12